Home2020-01-23T19:50:26+00:00
Loading...
Loading...

Spotlight

Twitter feed

Now available: Our newly updated guideline on selection of optimal adjuvant chemo and targeted therapy for #breastcancer https://t.co/Tpg2OKyaAC @ndenduluri1 et al #bcsm #breastcancerawareness

Congratulations to Leah Schmidt, PhD, one of the recipients of the 2020 AACR-AstraZeneca Immuno-oncology Research Fellowship. We look forward to her findings on obstacles associated with T cell therapy in lung cancer and potential strategies for safely enhancing ACT efficacy.

We invite applications for the 2021 Breast Cancer Research Foundation-AACR Career Development Awards to Promote Diversity and Inclusion. These two-year, $150,000 grants support projects investigating innovative approaches to breast cancer treatment:
https://t.co/tvIItBJ79Q

We congratulate Maria Casanova-Acebes, PhD, one of the recipients of the 2020 AACR-AstraZeneca Immuno-oncology Research Fellowship. We look forward to her findings on the functional contribution of macrophage subsets on tumor growth and immunotherapy response of lung cancers.

Due Oct 30:
Competitive Letters of Intent are invited from #Fellows for the AACR-John and Elizabeth Leonard Family Foundation Basic Cancer Research Fellowship. The fellowship provides $120,000 over two years to support mentored basic cancer research.
https://t.co/j4r65vlsgC

New #JCOCCI article details the process of how #CancerLinQ ingests #EHR data. https://t.co/7bN8WVK82C

“If you look at all types of cancer survivors as a group, certainly endocrinopathies are among the most common late effects, occurring in at least 40% to 50% of children,” Laurie Cohen, MD, of @DFBC_PedCare told @GoHealio:

Pediatric cancer survivors often face endocrine, cardiometabolic issues later in life

Children with cancer are particularly vulnerable to the adverse effects of treatments such as chemotherapy, radiation and hematopoietic stem cell tran...

ms.spr.ly

DYK: 64% of Americans report having a cancer screening test delayed or cancelled due to #COVID19. More #ASCOCancerSurvey findings here ➡️ https://t.co/MUNiq3jlAM

Recent publications

Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib. Clin Cancer Res.

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer.

All publications

Announcements

We’re pleased to share a new section on our site, “Our stories,” which will profile staff from the Belfer team. Our first story is Sarah Musoke (Nzikoba). Read Sarah’s story.

Research

Target identification and validation image
Target identification and validation
Photo of scientist carefully adding fluid to multiple test tubes
Drug discovery and development
Photo of Belfer Center researcher working at computer
Clinical science and correlatives

Strategic alliances

Graphic showing circular relationship of research, medicine, and industry

Our strategic alliances drive research innovations and lead to improved therapies to benefit cancer patients

Collaborate with us

Our people

Background image is a collage of photos showing Belfer Center members
Our team
Our culture
Background image is a collage of photos showing Belfer Center members

Donor highlight

Robert and Renée Belfer’s transformative cumulative Dana-Farber investment of more than $25 million launched the Robert A. and Renée E. Belfer Center for Applied Cancer Science. Their generosity enabled the Belfer Center to integrate its scientific teams, produce innovative cancer models, partner with industry leaders, and accelerate the development of revolutionary therapies to treat cancer. We are grateful for their vision and incredible support.

Photo of donors, Mr. and Mrs Belfer
Go to Top